

# Clinical trials of immune checkpoint inhibition for advanced renal-cell carcinoma in all type of patients

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 anti PD-L1

Trial	Treatments	Patients	Trials design and methods
<b>atezolizumab (MPDL3280A) vs</b>			
<b>NCT02420821</b> <i>ongoing</i> [NCT02420821] n=NA	-	-	

## References

NCT02420821, :

## 2 anti PD1

Trial	Treatments	Patients	Trials design and methods
<b>pembrolizumab vs chemotherapy</b>			
<b>KEYNOTE-045</b> , 2017 [NCT02256436] n=NA follow-up:	pemnrolizumab dose of 200 mg every 3 weeks versus investigator's choice of chemotherapy with paclitaxel, docetaxel, or vinflunine	patients with advanced urothelial cancer that recurred or progressed after platinum-based chemotherapy	Parallel groups open-label
<b>nivolumab vs everolimus</b>			
<b>Chekmate 025 (Motzer)</b> , 2015 [NCT01668784] n=NA follow-up:	3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks versus 10-mg everolimus tablet orally once daily	patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy	Parallel groups open-label

## References

### KEYNOTE-045, 2017:

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, Necchi A, Gerritsen W, Gurney H, Quinn DI, Culine S, Sternberg CN, Mai Y, Poehlein CH, Perini RF, Bajorin DF Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med 2017;376:1015-1026 [[28212060](#)]

### Chekmate 025 (Motzer), 2015:

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, R Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med

### 3 anti PD1 in association

Trial	Treatments	Patients	Trials design and methods
<b>Avelumab With Axitinib vs sunitinib</b>			
JAVELIN Renal 101 <i>ongoing</i> [NCT02684006] n=NA	-	-	
<b>nivolumab + ipilimumab vs sunitinib</b>			
CheckMate-214 , 2017 [NCT02231749] n=NA follow-up:	nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by Opdivo 3 mg/kg every 2 weeks versus sunitinib 50 mg once daily for 4 weeks, followed by 2 weeks off before continuation of treatment	intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma	Parallel groups open-label

### References

JAVELIN Renal 101, :  
CheckMate-214, 2017:

### 4 About TrialResults-center.org

TrialResults-center is an innovative knowledge database that collects the results of RCTs and provides dynamic interactive systematic reviews and meta-analysis in the field of all major heart and vessels diseases.

The TrialResults-center database provides a unique view of the treatment efficacy based on all data provided directly from clinical trial results, offering a valuable alternative to personal bibliographic search, published meta-analysis, etc. Furthermore, it would allow comparing easily the various concurrent therapeutic for the same clinical condition.

Rigorous meta-analysis method is used to populate TrialResults-center: widespread search of published and non published trials, study selection using pre-specified criteria, data extraction using standard form.

TrialResults-center is continually updated on a weekly basis. We continually search all new results (whatever their publication channel) and these news results are immediately added to the database with a maximum of 1 week.

TrialResults-center is non-profit and self-funded.